Citations (137)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (27)
Tommy Tsang Cheung, Tu H Mai, Yen Lin Chia, Desmond YH Yap, Chi-Ho Lee, Cecil Chi-Keung Chen, Ying Huang, Yuwen Jin, James Johnston, Viktoria Werkström, Yuhui Yao, Xiaoyun Ge & Wenying Zheng. (2023) Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants. Drug Design, Development and Therapy 17, pages 209-218.
Read now
Read now
L. Klimek, J. Hagemann, T. Huppertz, F. Bärhold, T. Albrecht, F. Klimek, I. Casper, M. Cuevas, C. Bergmann & S. Becker. (2023) COVID-19 and chronic rhinosinusitis: management and comorbidity – what have we learned?. Expert Review of Clinical Immunology 19:11, pages 1399-1406.
Read now
Read now
Sonsoles Tamarit-Sebastian, Francisco Miguel Ferrer-Soler & Alfredo J Lucendo. (2022) Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opinion on Investigational Drugs 31:2, pages 193-210.
Read now
Read now
Justin C Morse, Craig Miller & Brent Senior. (2021) Management of Chronic Rhinosinusitis with Nasal Polyposis in the Era of Biologics. Journal of Asthma and Allergy 14, pages 873-882.
Read now
Read now
Nora Drick, Katrin Milger, Benjamin Seeliger, Jan Fuge, Stephanie Korn, Roland Buhl, Maren Schuhmann, Felix Herth, Benjamin Kendziora, Juergen Behr, Nikolaus Kneidinger, Karl-Christian Bergmann, Christian Taube, Tobias Welte & Hendrik Suhling. (2020) Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma. Journal of Asthma and Allergy 13, pages 605-614.
Read now
Read now
Garry M. Walsh. (2020) Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update. Expert Opinion on Biological Therapy 20:10, pages 1237-1244.
Read now
Read now
Amelia Licari, Riccardo Castagnoli, Maria De Filippo, Thomas Foiadelli, Maria Angela Tosca, Gian Luigi Marseglia & Giorgio Ciprandi. (2020) Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis. Expert Opinion on Biological Therapy 20:6, pages 609-619.
Read now
Read now
Marco Caminati, Diego Bagnasco, Rachele Vaia & Gianenrico Senna. (2019) New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic. Biologics: Targets and Therapy 13, pages 89-95.
Read now
Read now
Francesco Menzella, Manuela Latorre, Patrizia Ruggiero, Diego Bagnasco & Enrico Heffler. (2019) Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?. Expert Opinion on Biological Therapy 19:7, pages 601-606.
Read now
Read now
Diego Bagnasco, Enrico Heffler, Elisa Testino, Giovanni Passalacqua & Giorgio Walter Canonica. (2019) Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opinion on Drug Metabolism & Toxicology 15:2, pages 113-120.
Read now
Read now
Corrado Pelaia, Alessandro Vatrella, Andrea Bruni, Rosa Terracciano & Girolamo Pelaia. (2018) Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Design, Development and Therapy 12, pages 619-628.
Read now
Read now
Juan Carlos Murillo, Ves Dimov & Alexei Gonzalez-Estrada. (2018) An evaluation of fevipiprant for the treatment of asthma: a promising new therapy?. Expert Opinion on Pharmacotherapy 19:18, pages 2087-2093.
Read now
Read now
Garry M. Walsh. (2018) Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma. Expert Review of Respiratory Medicine 12:11, pages 957-963.
Read now
Read now
Bao-ping Tian, Gen-sheng Zhang, Jian Lou, Hong-bin Zhou & Wei Cui. (2018) Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials. Journal of Asthma 55:9, pages 956-965.
Read now
Read now
Daniel Colodenco, Oscar Palomares, Carlos Celis, Alan Kaplan & Christian Domingo. (2018) Moving toward consensus on diagnosis and management of severe asthma in adults. Current Medical Research and Opinion 34:3, pages 387-399.
Read now
Read now
Francesco Menzella, Carla Galeone, Francesca Bertolini, Claudia Castagnetti & Nicola Facciolongo. (2017) Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?. Journal of Asthma and Allergy 10, pages 237-247.
Read now
Read now
Maria Gabriella Matera, Luigino Calzetta, Barbara Rinaldi & Mario Cazzola. (2017) Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opinion on Drug Metabolism & Toxicology 13:9, pages 1007-1013.
Read now
Read now
Sabina Antonela Antoniu. (2017) Benralizumab as a potential treatment of asthma. Expert Opinion on Biological Therapy 17:7, pages 895-900.
Read now
Read now
Tara Vinyette Saco, Amber N. Pepper & Richard F. Lockey. (2017) Benralizumab for the treatment of asthma. Expert Review of Clinical Immunology 13:5, pages 405-413.
Read now
Read now
Garry M. Walsh. (2017) Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma – an update. Expert Review of Clinical Immunology 13:2, pages 143-149.
Read now
Read now
Francesco Menzella, Mirco Lusuardi, Gloria Montanari, Carla Galeone, Nicola Facciolongo & Luigi Zucchi. (2016) Clinical usefulness of mepolizumab in severe eosinophilic asthma. Therapeutics and Clinical Risk Management 12, pages 907-916.
Read now
Read now
Laren D Tan, Jennifer M Bratt, Dorottya Godor, Samuel Louie & Nicholas J Kenyon. (2016) Benralizumab: a unique IL-5 inhibitor for severe asthma. Journal of Asthma and Allergy 9, pages 71-81.
Read now
Read now
Con Panousis, Urmi Dhagat, Kirsten M. Edwards, Veronika Rayzman, Matthew P. Hardy, Hal Braley, Gail M. Gauvreau, Timothy R. Hercus, Steven Smith, Roma Sehmi, Laura McMillan, Mara Dottore, Barbara J. McClure, Louis J. Fabri, Gino Vairo, Angel F Lopez, Michael W. Parker, Andrew D. Nash, Nicholas J. Wilson, Michael J. Wilson & Catherine M. Owczarek. (2016) CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors. mAbs 8:3, pages 436-453.
Read now
Read now
Megan F Patterson, Larry Borish & Joshua L Kennedy. (2015) The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. Journal of Asthma and Allergy 8, pages 125-134.
Read now
Read now
Juan Carlos Cardet & Elliot Israel. (2015) Update on reslizumab for eosinophilic asthma. Expert Opinion on Biological Therapy 15:10, pages 1531-1539.
Read now
Read now
Philip M Hansbro, Grace V Scott, Ama-Tawiah Essilfie, Richard Y Kim, Malcolm R Starkey, Duc H Nguyen, Paul D Allen, Gerard E Kaiko, Ming Yang, Jay C Horvat & Paul S Foster. (2013) Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opinion on Investigational Drugs 22:1, pages 49-69.
Read now
Read now
Nestor A Molfino. (2012) Targeting of eosinophils in asthma. Expert Opinion on Biological Therapy 12:7, pages 807-809.
Read now
Read now
Articles from other publishers (110)
Hsuan-Chi Chen, Chuang-Wei Wang, Wu Han Toh, Hua-En Lee, Wen-Hung Chung & Chun-Bing Chen. (2023) Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches. Clinical Reviews in Allergy & Immunology.
Crossref
Crossref
Aarti Pandya, Esosa Adah, Bridgette Jones & Rachel Chevalier. (2023) The evolving landscape of immunotherapy for the treatment of allergic conditions. Clinical and Translational Science 16:8, pages 1294-1308.
Crossref
Crossref
Michael J. AW & Shaun J. KILTY. (2023) Advances in biologic therapies for chronic rhinosinusitis with nasal polyps. Otorhinolaryngology 73:2.
Crossref
Crossref
Eduardo Genofre, Donna Carstens, Wilfried DeBacker, Patrick Muchmore, Reynold A. PanettieriJrJr, Kirsty Rhodes, Vivian H. Shih & Frank Trudo. (2023) The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach. Respiratory Research 24:1.
Crossref
Crossref
Pattraporn Satitsuksanoa, Sayuri Iwasaki, Jolien Boersma, Manal Bel Imam, Stephan R. Schneider, Iris Chang, Willem van de Veen & Mübeccel Akdis. (2023) B cells: The many facets of B cells in allergic diseases. Journal of Allergy and Clinical Immunology.
Crossref
Crossref
Leonard B. Bacharier & Daniel J. Jackson. (2023) Biologics in the treatment of asthma in children and adolescents. Journal of Allergy and Clinical Immunology 151:3, pages 581-589.
Crossref
Crossref
Haruki Koike, Ryoji Nishi, Satoru Yagi, Soma Furukawa, Yuki Fukami, Masahiro Iijima & Masahisa Katsuno. (2022) A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis. Advances in Therapy 40:1, pages 25-40.
Crossref
Crossref
Michael J. Aw & Shaun J. Kilty. 2023. Nasal Physiology and Pathophysiology of Nasal Disorders. Nasal Physiology and Pathophysiology of Nasal Disorders
115
126
.
Gilda Varricchi, Sebastian Ferri, Jack Pepys, Remo Poto, Giuseppe Spadaro, Emanuele Nappi, Giovanni Paoletti, Johann Christian Virchow, Enrico Heffler & Walter G. Canonica. (2022) Biologics and airway remodeling in severe asthma. Allergy 77:12, pages 3538-3552.
Crossref
Crossref
Linlin Ma, Min Zhu, Guanghui Li, Junwei Gai, Yanfei Li, Huaiyu Gu, Peng Qiao, Xiaofei Li, Weiwei Ji, Rui Zhao, Yue Wu & Yakun Wan. (2022) Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma. Respiratory Research 23:1.
Crossref
Crossref
Irena Pintea, Ioana Adriana Muntean, Carmen Teodora Dobrican, Nicolae Miron & Diana Deleanu. (2022) Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS. Journal of Clinical Medicine 11:22, pages 6642.
Crossref
Crossref
Lorenzo Salvati, Francesco Liotta, Francesco Annunziato & Lorenzo Cosmi. (2022) Therapeutical Targets in Allergic Inflammation. Biomedicines 10:11, pages 2874.
Crossref
Crossref
Simone C. Oostindie, Greg A. Lazar, Janine Schuurman & Paul W. H. I. Parren. (2022) Avidity in antibody effector functions and biotherapeutic drug design. Nature Reviews Drug Discovery 21:10, pages 715-735.
Crossref
Crossref
Carmen Venegas Garrido, Manali Mukherjee, Anurag Bhalla & Parameswaran Nair. (2022) Airway autoimmunity, asthma exacerbations, and response to biologics. Clinical & Experimental Allergy.
Crossref
Crossref
Silpa T. Taunk, Juan C. Cardet & Dennis K. Ledford. (2022) Clinical implications of asthma endotypes and phenotypes. Allergy and Asthma Proceedings 43:5, pages 375-382.
Crossref
Crossref
Josée Golay, Alain E. Andrea & Irene Cattaneo. (2022) Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies. Frontiers in Immunology 13.
Crossref
Crossref
Junhu Tai, Munsoo Han & Tae Hoon Kim. (2022) Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets. International Journal of Molecular Sciences 23:10, pages 5523.
Crossref
Crossref
Kissy Guevara-Hoyer, Eduardo de la Fuente-Munoz, Celia Pinedo Sierra, Teresa Robledo & Silvia Sánchez-Ramón. (2022) To the Editor: “Complete Resolution of Multiple Warts after a First Dose of the Receptor Interleukin-5 Inhibitor”. Journal of Clinical Immunology 42:3, pages 684-687.
Crossref
Crossref
Ioannis Pantazopoulos, Kalliopi Magounaki, Ourania Kotsiou, Erasmia Rouka, Fotis Perlikos, Sotirios Kakavas & Konstantinos Gourgoulianis. (2022) Incorporating Biomarkers in COPD Management: The Research Keeps Going. Journal of Personalized Medicine 12:3, pages 379.
Crossref
Crossref
Hitasha Rupani, Jessica Gates, Joanne E. Kavanagh & David J. Jackson. 2022. Eosinophilic Lung Diseases. Eosinophilic Lung Diseases
73
99
.
Jacqueline Ho, Raquel Alvarado, Janet Rimmer, William A. Sewell, Sophie Walter, Peter Earls, Raewyn G. Campbell, Raymond Sacks, Larry H. Kalish & Richard J Harvey. (2021) Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis. American Journal of Rhinology & Allergy 36:1, pages 72-80.
Crossref
Crossref
Grace A. Kavanagh, Deborah Casey, Ruth P. Cusack, Barry J. Plant & Desmond M. Murphy. (2022) Creatine kinase levels in asthma patients receiving interleukin-5 therapy. Therapeutic Advances in Respiratory Disease 16, pages 175346662211224.
Crossref
Crossref
Yizhou Yin, Matthew G. Romei, Kannan Sankar, Lipika R. Pal, Kam Hon Hoi, Yanli Yang, Brandon Leonard, Gladys De Leon Boenig, Nikit Kumar, Marissa Matsumoto, Jian Payandeh, Seth F. Harris, John Moult & Greg A. Lazar. (2022) Antibody interfaces revealed through structural mining. Computational and Structural Biotechnology Journal 20, pages 4952-4968.
Crossref
Crossref
Silvano Dragonieri & Giovanna Elisiana Carpagnano. (2021) Biological therapy for severe asthma. Asthma Research and Practice 7:1.
Crossref
Crossref
Joanne E. Kavanagh, Andrew P. Hearn & David J. Jackson. (2022) A pragmatic guide to choosing biologic therapies in severe asthma. Breathe 17:4, pages 210144.
Crossref
Crossref
Olga N. Titova, Natalia A. Kuzubova, Daria B. Sklyarova & Maria A. Petrova. (2021) The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice. PULMONOLOGIYA 31:5, pages 628-634.
Crossref
Crossref
C. Landi, L. Vantaggiato, E. Shaba, P. Cameli, A. Carleo, M. d’Alessandro, L. Bergantini, E. Bargagli & L. Bini. (2021) Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment. Pulmonary Pharmacology & Therapeutics 70, pages 102060.
Crossref
Crossref
Alexander L. Schneider, Robert P. Schleimer & Bruce K. Tan. (2021) Targetable pathogenic mechanisms in nasal polyposis. International Forum of Allergy & Rhinology 11:8, pages 1220-1234.
Crossref
Crossref
Jody Tversky, Andrew P. Lane & Antoine Azar. (2021) Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double‐blind placebo‐controlled trial. Clinical & Experimental Allergy 51:6, pages 836-844.
Crossref
Crossref
Hiroaki Matsuura, Keiichi Fujiwara, Hiroki Omori, Kiriko Onishi, Tadahiro Kuribayashi, Sho Mitsumune, Yuki Takigawa, Kenichiro Kudo, Daisuke Minami, Akiko Sato, Ken Sato & Takuo Shibayama. (2021) Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan. Internal Medicine 60:9, pages 1443-1450.
Crossref
Crossref
Ruth P. Cusack, Christiane E. Whetstone, Yanqing Xie, Maral Ranjbar & Gail M. Gauvreau. (2021) Regulation of Eosinophilia in Asthma—New Therapeutic Approaches for Asthma Treatment. Cells 10:4, pages 817.
Crossref
Crossref
Mathieu Fieldes, Chloé Bourguignon, Said Assou, Amel Nasri, Aurélie Fort, Isabelle Vachier, John De Vos, Engi Ahmed & Arnaud Bourdin. (2021) Targeted therapy in eosinophilic chronic obstructive pulmonary disease. ERJ Open Research 7:2, pages 00437-2020.
Crossref
Crossref
Ludger Klimek, Marek Jutel, Jean Bousquet, Ioana Agache, Cezmi A. Akdis, Valerie Hox, Philippe Gevaert, Peter Valentin Tomazic, Carmen Rondon, Cemal Cingi, Sanna Toppila‐Salmi, Aspasia Karavelia, Banu Bozkurt, Ulrike Förster‐Ruhrmann, Sven Becker, Adam M. Chaker, Barbara Wollenberg, Ralph Mösges, Tilman Huppertz, Jan Hagemann, Claus Bachert & Wytske Fokkens. (2021) Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper. Allergy 76:3, pages 677-688.
Crossref
Crossref
Giulia Scioscia, Giovanna Elisiana Carpagnano, Carla Maria Irene Quarato, Donato Lacedonia, Sonia Santamaria, Piera Soccio, Annarita Depalo, Paolo Fuso & Maria Pia Foschino Barbaro. (2021) Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience. Frontiers in Pharmacology 12.
Crossref
Crossref
Srijit Ghosh, Srijita Das, Rupsa Mondal, Salik Abdullah, Shirin Sultana, Sukhbir Singh, Aayush Sehgal & Tapan Behl. (2021) A review on the effect of COVID-19 in type 2 asthma and its management. International Immunopharmacology 91, pages 107309.
Crossref
Crossref
Claudia Landi, Paolo Cameli, Lorenza Vantaggiato, Laura Bergantini, Miriana d'Alessandro, Marco Perruzza, Alfonso Carleo, Enxhi Shaba, Fabrizio Di Giuseppe, Stefania Angelucci, Elena Bargagli & Luca Bini. (2021) Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1869:2, pages 140563.
Crossref
Crossref
Kazuya Tsubouchi, Masako Arimura-Omori, Shigesato Inoue, Yuki Okamatsu, Katsuhiro Inoue & Taishi Harada. (2021) A case of allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia successfully treated with benralizumab. Respiratory Medicine Case Reports 32, pages 101339.
Crossref
Crossref
Annina Lyly, Anu Laulajainen-Hongisto, Philippe Gevaert, Paula Kauppi & Sanna Toppila-Salmi. (2020) Monoclonal Antibodies and Airway Diseases. International Journal of Molecular Sciences 21:24, pages 9477.
Crossref
Crossref
Andrew P. Hearn, Brian D. Kent & David J. Jackson. (2020) Biologic treatment options for severe asthma. Current Opinion in Immunology 66, pages 151-160.
Crossref
Crossref
Aasha Harish & Stanley A. Schwartz. (2020) Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions. Clinical Reviews in Allergy & Immunology 59:2, pages 231-247.
Crossref
Crossref
Lorenza Vantaggiato, Marco Perruzza, Rosa Metella Refini, Laura Bergantini, Miriana d’Alessandro, Paolo Cameli, Davide Perruzza, Luca Bini, Elena Bargagli & Claudia Landi. (2020) Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study. Lung 198:5, pages 761-765.
Crossref
Crossref
Ian F. Slack, Justin T. Schwartz, Vincent A. Mukkada, Shawna Hottinger & J. Pablo Abonia. (2020) Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine. Current Allergy and Asthma Reports 20:8.
Crossref
Crossref
Luciana P. Tavares, Hong Yong Peh, Wan Shun Daniel Tan, Hadas Pahima, Pasquale Maffia, Ekaterini Tiligada & Francesca Levi-Schaffer. (2020) Granulocyte-targeted therapies for airway diseases. Pharmacological Research 157, pages 104881.
Crossref
Crossref
Michael C Peters & Sally E Wenzel. (2020) Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. The Lancet 395:10221, pages 371-383.
Crossref
Crossref
Geoffrey Lowell ChuppRavdeep Kaur & Anne Mainardi. (2020) New Therapies for Emerging Endotypes of Asthma. Annual Review of Medicine 71:1, pages 289-302.
Crossref
Crossref
Corrado Pelaia, Giovanni Paoletti, Francesca Puggioni, Francesca Racca, Girolamo Pelaia, Giorgio Walter Canonica & Enrico Heffler. (2019) Interleukin-5 in the Pathophysiology of Severe Asthma. Frontiers in Physiology 10.
Crossref
Crossref
Kareem Khalaf, Giovanni Paoletti, Francesca Puggioni, Francesca Racca, Fabrizio De Luca, Veronica Giorgis, Giorgio Walter Canonica & Enrico Heffler. (2019) Asthma from immune pathogenesis to precision medicine. Seminars in Immunology 46, pages 101294.
Crossref
Crossref
Ravdeep Kaur & Geoffrey Chupp. (2019) Phenotypes and endotypes of adult asthma: Moving toward precision medicine. Journal of Allergy and Clinical Immunology 144:1, pages 1-12.
Crossref
Crossref
N. Giang, T. Villeneuve, L. Pelletier & M. Savignac. (2019) Les canaux calciques Cav1 comme cible thérapeutique dans l’asthme allergique. Revue Française d'Allergologie 59:4, pages 329-335.
Crossref
Crossref
Ian D. Pavord & Nicola A. Hanania. (2019) Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. The Journal of Allergy and Clinical Immunology: In Practice 7:5, pages 1430-1436.
Crossref
Crossref
Leo Koenderman. (2019) Inside-Out Control of Fc-Receptors. Frontiers in Immunology 10.
Crossref
Crossref
Alison G. Kartush, Jane K. Schumacher, Rachna Shah & Monica O. Patadia. (2018) Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps. American Journal of Rhinology & Allergy 33:2, pages 203-211.
Crossref
Crossref
Laurent Guilleminault & Alain Didier. (2019) L’asthme sévère à l’ère des biothérapies. La Presse Médicale 48:3, pages 310-321.
Crossref
Crossref
Sung-Ryeol KimJae-Hyun Lee. (2019) Biologic agents for asthma treatment. Allergy, Asthma & Respiratory Disease 7:1, pages 3.
Crossref
Crossref
Ian D. Pavord. (2019) Oral corticosteroid-dependent asthma. Current Opinion in Pulmonary Medicine 25:1, pages 51-58.
Crossref
Crossref
Frank R. Brennan, Emma Smith & Sherri Dudal. 2019. Nijkamp and Parnham's Principles of Immunopharmacology. Nijkamp and Parnham's Principles of Immunopharmacology
369
406
.
Maike vom Hove, Martina P. Neininger, Thilo Bertsche & Freerk Prenzel. 2020. Pediatric Pharmacotherapy. Pediatric Pharmacotherapy
131
151
.
Erica Ollmann Saphire, Sharon L. Schendel, Bronwyn M. Gunn, Jacob C. Milligan & Galit Alter. (2018) Antibody-mediated protection against Ebola virus. Nature Immunology 19:11, pages 1169-1178.
Crossref
Crossref
Imran H. Iftikhar, Mathew Schimmel, William Bender, Colin Swenson & David Amrol. (2018) Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis. Lung 196:5, pages 517-530.
Crossref
Crossref
T. Sécher, L. Guilleminault, K. Reckamp, I. Amanam, L. Plantier & N. Heuzé-Vourc'h. (2018) Therapeutic antibodies: A new era in the treatment of respiratory diseases?. Pharmacology & Therapeutics 189, pages 149-172.
Crossref
Crossref
Peter J. Barnes. (2018) Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology 18:7, pages 454-466.
Crossref
Crossref
Joshua B. Wechsler & Ikuo Hirano. (2018) Biological therapies for eosinophilic gastrointestinal diseases. Journal of Allergy and Clinical Immunology 142:1, pages 24-31.e2.
Crossref
Crossref
Garry M Walsh. (2018) Reslizumab in the treatment of severe eosinophilic asthma: an update. Immunotherapy 10:8, pages 695-698.
Crossref
Crossref
Xia Xu, Jin-Fu Xu, Guoxing Zheng, Hai-Wen Lu, Jie-Lin Duan, Wei Rui, Jian-Hong Guan, Li-Qing Cheng, Dan-Dan Yang, Ming-Chao Wang, Quan-Zhen Lv, Jian-Xiong Li, Xueqiang Zhao, Chun-Xia Chen, Peng Shi, Xin-Ming Jia & Xin Lin. (2018) CARD9S12N facilitates the production of IL-5 by alveolar macrophages for the induction of type 2 immune responses. Nature Immunology 19:6, pages 547-560.
Crossref
Crossref
Ting Liu, Faping Wang, Geng Wang & Hui Mao. (2017) Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. Frontiers of Medicine 12:3, pages 340-349.
Crossref
Crossref
Massimo Caruso, Jaymin Morjaria, Rosalia Emma, Maria Domenica Amaradio & Riccardo Polosa. (2017) Biologic agents for severe asthma patients: clinical perspectives and implications. Internal and Emergency Medicine 13:2, pages 155-176.
Crossref
Crossref
Corrado Pelaia, Cecilia Calabrese, Alessandro Vatrella, Maria Teresa Busceti, Eugenio Garofalo, Nicola Lombardo, Rosa Terracciano & Girolamo Pelaia. (2018) Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International 2018, pages 1-9.
Crossref
Crossref
Maryam Hussain, Loïc Borcard, Kevin P. Walsh, Maria Pena Rodriguez, Christoph Mueller, Brian S. Kim, Masato Kubo, David Artis & Mario Noti. (2018) Basophil-derived IL-4 promotes epicutaneous antigen sensitization concomitant with the development of food allergy. Journal of Allergy and Clinical Immunology 141:1, pages 223-234.e5.
Crossref
Crossref
Ian D Pavord, Richard Beasley, Alvar Agusti, Gary P Anderson, Elisabeth Bel, Guy Brusselle, Paul Cullinan, Adnan Custovic, Francine M Ducharme, John V Fahy, Urs Frey, Peter Gibson, Liam G Heaney, Patrick G Holt, Marc Humbert, Clare M Lloyd, Guy Marks, Fernando D Martinez, Peter D Sly, Erika von Mutius, Sally Wenzel, Heather J Zar & Andy Bush. (2018) After asthma: redefining airways diseases. The Lancet 391:10118, pages 350-400.
Crossref
Crossref
Harold Kim, Anne K. Ellis, David Fischer, Mary Noseworthy, Ron Olivenstein, Kenneth R. Chapman & Jason Lee. (2017) Asthma biomarkers in the age of biologics. Allergy, Asthma & Clinical Immunology 13:1.
Crossref
Crossref
Steven W. Yancey, Oliver N. Keene, Frank C. Albers, Hector Ortega, Stewart Bates, Eugene R. Bleecker & Ian Pavord. (2017) Biomarkers for severe eosinophilic asthma. Journal of Allergy and Clinical Immunology 140:6, pages 1509-1518.
Crossref
Crossref
Elisabeth H. Bel & Anneke ten Brinke. (2017) New Anti-Eosinophil Drugs for Asthma and COPD. Chest 152:6, pages 1276-1282.
Crossref
Crossref
Jordan Glicksman & John V Bosso. (2017) New and Emerging Biological Medications for Asthma, Allergic Rhinitis and Chronic Rhinosinusitis: a Concise Review. Current Otorhinolaryngology Reports 5:4, pages 201-211.
Crossref
Crossref
Diego Bagnasco, Matteo Ferrando, Gilda Varricchi, Francesca Puggioni, Giovanni Passalacqua & Giorgio Walter Canonica. (2017) Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Frontiers in Medicine 4.
Crossref
Crossref
Diego Bagnasco, Matteo Ferrando, Marco Caminati, Alice Bragantini, Francesca Puggioni, Gilda Varricchi, Giovanni Passalacqua & Giorgio Walter Canonica. (2017) Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations. Drug Safety 40:7, pages 559-570.
Crossref
Crossref
Rahul Shrimanker & Ian D. Pavord. (2017) Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook. BioDrugs 31:2, pages 93-103.
Crossref
Crossref
Lynne A Murray, Chris Grainge, Peter A Wark & Darryl A Knight. (2017) Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF. Pharmacology & Therapeutics 169, pages 1-12.
Crossref
Crossref
Girolamo Pelaia, Alessandro Vatrella & Rosario MaselliGirolamo Pelaia, Alessandro Vatrella & Rosario Maselli. 2017. Asthma: Targeted Biological Therapies. Asthma: Targeted Biological Therapies
51
66
.
Francesco Menzella, Mirco Lusuardi, Carla Galeone, Sofia Taddei, Nicola Facciolongo & Luigi Zucchi. (2016) Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential. Therapeutic Advances in Chronic Disease 7:6, pages 260-277.
Crossref
Crossref
Caroline Sattler, Roxane Malrin, Gilles Garcia & Marc Humbert. (2016) Les traitements du futur de l’asthme sévère. La Presse Médicale 45:11, pages 1043-1055.
Crossref
Crossref
Ibrahim Sulaiman, Jonathan Chee Woei Lim, Hon Liong Soo & Johnson Stanslas. (2016) Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation. Pulmonary Pharmacology & Therapeutics 40, pages 52-68.
Crossref
Crossref
J Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Gary T Ferguson, William W Busse, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Viktoria Werkström, Magnus Aurivillius & Mitchell Goldman. (2016) Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet 388:10056, pages 2128-2141.
Crossref
Crossref
Kent Lam, Robert C. Kern & Amber Luong. (2016) Is there a future for biologics in the management of chronic rhinosinusitis?. International Forum of Allergy & Rhinology 6:9, pages 935-942.
Crossref
Crossref
Peter Sondermann & David E Szymkowski. (2016) Harnessing Fc receptor biology in the design of therapeutic antibodies. Current Opinion in Immunology 40, pages 78-87.
Crossref
Crossref
Vikas Uppal, Portia Kreiger & Erika Kutsch. (2015) Eosinophilic Gastroenteritis and Colitis: a Comprehensive Review. Clinical Reviews in Allergy & Immunology 50:2, pages 175-188.
Crossref
Crossref
Tuyet-Hang Pham, Gautam Damera, Paul Newbold & Koustubh Ranade. (2016) Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respiratory Medicine 111, pages 21-29.
Crossref
Crossref
Koichi ANDO, Akihiko TANAKA, Takuya YOKOE, Tsukasa OHNISHI, Shin INOUE & Hironori SAGARA. (2016) Meta-analysis of Low-versus High-dose Benralizumab in Adults with Uncontrolled Eosinophilic Asthma. The Showa University Journal of Medical Sciences 28:4, pages 337-347.
Crossref
Crossref
Leena George & Christopher E. Brightling. (2015) Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Therapeutic Advances in Chronic Disease 7:1, pages 34-51.
Crossref
Crossref
Puxeddu Ilaria, Levi-Schaffer Francesca & Migliorini Paola. 2016. Immune Rebalancing. Immune Rebalancing
85
103
.
M. Röcken, T. Biedermann & H. Renz. 2016. Allergologie. Allergologie
641
651
.
Patrick D. Mitchell, Amani I. El-Gammal & Paul M. O’Byrne. 2017. Pharmacology and Therapeutics of Asthma and COPD. Pharmacology and Therapeutics of Asthma and COPD
131
152
.
PD Mitchell, AI El-Gammal & PM O'Byrne. (2016) Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. Clinical Pharmacology & Therapeutics 99:1, pages 38-48.
Crossref
Crossref
Christopher Brightling, Millie Wang, Martin Braddock, Lars Nordenmark, Mattis Gottlow & Gene Colice. (2015) MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma. Clinical Investigation 5:8, pages 713-722.
Crossref
Crossref
Garry M. Walsh. (2015) Mepolizumab-based therapy in asthma. Current Opinion in Allergy & Clinical Immunology 15:4, pages 392-396.
Crossref
Crossref
Haley M. Hoy & Louise C. O'Keefe. (2015) Practical guidance on the recognition of uncontrolled asthma and its management. Journal of the American Association of Nurse Practitioners 27:8, pages 466-475.
Crossref
Crossref
O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, O. Palomares, C. Schmidt-Weber, H.-U. Simon, U. C. Steiner, A. Vultaggio, C. A. Akdis & F. Spertini. (2015) EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders. Allergy 70:7, pages 727-754.
Crossref
Crossref
Abdol A. Ameri. (2015) Die verschiedenen Facetten der zukünftigen Biologika-Therapien. Pneumo News 7:2, pages 44-46.
Crossref
Crossref
Christina Hartwig, Antje Munder, Silke Glage, Dirk Wedekind, Heiko Schenk, Roland Seifert & Detlef Neumann. (2015)
The histamine H
4
‐receptor (H
4
R) regulates eosinophilic inflammation in ovalbumin‐induced experimental allergic asthma in mice
. European Journal of Immunology 45:4, pages 1129-1140.
Crossref
Crossref
Jared Darveaux & William W. Busse. (2015) Biologics in Asthma—The Next Step Toward Personalized Treatment. The Journal of Allergy and Clinical Immunology: In Practice 3:2, pages 152-160.
Crossref
Crossref
Yingying Shen, Xiaomei Ren, Ke Ding, Zhang Zhang, Deping Wang & Jingxuan Pan. (2014) Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells. Oncotarget 5:21, pages 10407-10420.
Crossref
Crossref
Frank R. Brennan. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
969
1078
.
Glenn T. Furuta, F. Dan Atkins, Nancy A. Lee & James J. Lee. (2014) Changing roles of eosinophils in health and disease. Annals of Allergy, Asthma & Immunology 113:1, pages 3-8.
Crossref
Crossref
Jeffrey B. Bice, Evelyn Leechawengwongs & Anthony Montanaro. (2014) Biologic targeted therapy in allergic asthma. Annals of Allergy, Asthma & Immunology 112:2, pages 108-115.
Crossref
Crossref
Manali Mukherjee, Roma Sehmi & Parameswaran Nair. (2014) Anti-IL5 therapy for asthma and beyond. World Allergy Organization Journal 7, pages 32.
Crossref
Crossref
Nathan Hambly & Parameswaran Nair. (2014) Monoclonal antibodies for the treatment of refractory asthma. Current Opinion in Pulmonary Medicine 20:1, pages 87-94.
Crossref
Crossref
Rachid Berair & Ian D. Pavord. (2013) Rationale and Clinical Results of Inhibiting Interleukin-5 for the Treatment of Severe Asthma. Current Allergy and Asthma Reports 13:5, pages 469-476.
Crossref
Crossref
G. J. Gleich, A. D. Klion, J. J. Lee & P. F. Weller. (2013) The consequences of not having eosinophils. Allergy 68:7, pages 829-835.
Crossref
Crossref
Garry M. Walsh. (2013) Eosinophil Apoptosis and Clearance in Asthma. Journal of Cell Death 6, pages JCD.S10818.
Crossref
Crossref
Girolamo Pelaia, Alessandro Vatrella & Rosario Maselli. (2012) The potential of biologics for the treatment of asthma. Nature Reviews Drug Discovery 11:12, pages 958-972.
Crossref
Crossref
Elizabeth A. JacobsenRichard A. Helmers, James J. LeeNancy A. Lee. (2012) The expanding role(s) of eosinophils in health and disease. Blood 120:19, pages 3882-3890.
Crossref
Crossref